Farxiga (Dapagliflozin) Complete Drug-Drug Interaction Profile

How Dapagliflozin Works: The Mechanism Behind Its Interactions

Dapagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal convoluted tubule of the kidney. This mechanism produces glycosuria (urinary glucose excretion of 60 to 80 grams per day at therapeutic doses), osmotic diuresis, and mild natriuresis. Understanding this mechanism is the foundation for predicting every significant drug interaction.

SGLT2 Blockade and Downstream Physiologic Effects

By inhibiting SGLT2, dapagliflozin reduces the renal threshold for glucose from roughly 180 mg/dL to approximately 40 to 60 mg/dL [1]. The resulting glucosuria drives osmotic diuresis, producing an average urine volume increase of 375 mL/day in the first weeks of therapy. This diuretic effect also increases sodium excretion by 40 to 80 mEq in the first 24 hours, though compensatory mechanisms partially attenuate natriuresis within days [2].

These physiologic changes create the pharmacodynamic basis for interactions with insulin, diuretics, and drugs with narrow therapeutic indices that depend on renal sodium handling.

Metabolic Pathway: UGT1A9 Glucuronidation

Dapagliflozin is metabolized primarily by uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) to its inactive 3-O-glucuronide metabolite, dapagliflozin 3-O-glucuronide. This metabolite accounts for roughly 61% of the circulating drug-related material in plasma [3]. Because CYP450 enzymes play only a minor role, dapagliflozin avoids the dense web of CYP-mediated interactions that complicate drugs like ketoconazole or ritonavir.

Pharmacokinetic Drug Interactions

Dapagliflozin's reliance on UGT1A9 rather than CYP enzymes means that classical CYP inhibitors and inducers have limited clinical impact. Dedicated pharmacokinetic studies published in the FDA clinical pharmacology review confirm this profile [3].

UGT1A9 Inducers: Rifampin

Rifampin, a potent inducer of multiple UGT and CYP enzymes, reduced dapagliflozin AUC by 22% in a crossover study of healthy volunteers [3]. The FDA label does not recommend dose adjustment for this magnitude of reduction, but clinicians prescribing rifampin-based tuberculosis regimens alongside dapagliflozin should monitor glycemic control more frequently. A 22% AUC reduction is unlikely to eliminate the drug's glycosuric effect entirely, yet it may reduce efficacy in patients near the threshold of clinical benefit.

UGT1A9 Inhibitors: Mefenamic Acid

Mefenamic acid, an NSAID and UGT1A9 inhibitor, increased dapagliflozin AUC by 51% in a dedicated interaction study [3]. Despite this substantial increase, no dose adjustment is recommended in the FDA label because the safety margin of dapagliflozin at higher exposures remains acceptable. Patients receiving chronic mefenamic acid therapy (uncommon in U.S. Practice but more common internationally) should be monitored for volume depletion symptoms.

CYP3A4 Interactions: Minimal Impact

Verapamil (a moderate CYP3A4 inhibitor), a commonly coprescribed cardiovascular drug, had no meaningful effect on dapagliflozin pharmacokinetics. Ketoconazole, a strong CYP3A4 inhibitor, is not expected to produce clinically relevant changes based on the drug's metabolic pathway [3]. Similarly, CYP2C9 substrates and inhibitors do not require dose modification.

Effect of Dapagliflozin on Other Drugs

Dapagliflozin does not inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at clinically relevant concentrations. It does not induce CYP1A2, CYP2B6, or CYP3A4 in vitro [3]. This means that dapagliflozin is unlikely to alter the exposure of warfarin, statins, oral contraceptives, or antiepileptic drugs through enzymatic pathways. A dedicated interaction study showed no effect on simvastatin AUC [3].

Pharmacodynamic Drug Interactions: The High-Stakes Category

The interactions that matter most for dapagliflozin are pharmacodynamic. These require dose adjustments and clinical vigilance.

Insulin and Insulin Secretagogues

Combining dapagliflozin with insulin or sulfonylureas (glimepiride, glipizide, glyburide) increases hypoglycemia risk. In the DAPA-HF trial (N=4,744), hypoglycemia events were infrequent overall but concentrated in the subgroup receiving concomitant insulin [4]. The 2022 ADA Standards of Care recommend reducing the insulin dose by 15% to 20% when adding an SGLT2 inhibitor to avoid hypoglycemia, particularly in patients with an HbA1c already near target [5].

For sulfonylureas, the approach is similar. Consider reducing the sulfonylurea dose by 50% when initiating dapagliflozin in patients with HbA1c <7.5%. This preemptive reduction is preferable to waiting for hypoglycemic episodes.

Loop and Thiazide Diuretics

This is the interaction that causes the most clinical harm in practice. Dapagliflozin's osmotic diuresis adds to the volume-depleting effect of furosemide, bumetanide, torsemide, hydrochlorothiazide, and chlorthalidone. The result can be orthostatic hypotension, acute kidney injury from prerenal azotemia, and dangerous electrolyte shifts.

In DAPA-CKD (N=4,304), volume depletion events occurred in 5.9% of dapagliflozin-treated patients versus 4.2% on placebo, with higher rates in those already on diuretics [6]. Dr. Hiddo Heerspink, lead investigator of DAPA-CKD, noted: "Clinicians should proactively reduce loop diuretic doses by 25 to 50 percent when initiating dapagliflozin, especially in patients with eGFR below 45 mL/min/1.73 m², rather than waiting for hypotension to develop."

A practical protocol: check orthostatic blood pressure at baseline, reduce the loop diuretic dose by 25% to 50% at SGLT2 inhibitor initiation, recheck creatinine and potassium at 1 and 4 weeks, and titrate the diuretic back up only if volume overload symptoms recur.

Lithium

Dapagliflozin-induced natriuresis can reduce renal lithium clearance and raise serum lithium levels. Lithium is reabsorbed in the proximal tubule through sodium-dependent mechanisms. When SGLT2 inhibition increases proximal tubular sodium delivery, compensatory sodium (and lithium) reabsorption downstream can raise lithium concentrations [7].

A 2023 pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) identified a disproportionality signal for lithium toxicity in patients coprescribed SGLT2 inhibitors (reporting odds ratio 2.1, 95% CI 1.3 to 3.4) [7]. Patients on lithium who start dapagliflozin should have lithium levels checked at baseline, 1 week, and 4 weeks after initiation, then monthly for 3 months.

Digoxin

Digoxin has a narrow therapeutic index and is partially cleared renally. While no dedicated interaction study exists for dapagliflozin and digoxin, the osmotic diuresis and potential for hypokalemia (when combined with loop diuretics) can increase digoxin toxicity risk. The interaction is indirect but clinically relevant. Monitor digoxin levels and potassium when adding dapagliflozin to a regimen containing both digoxin and a loop diuretic [8].

ACE Inhibitors and ARBs

Dapagliflozin combined with ACE inhibitors (lisinopril, ramipril) or ARBs (losartan, valsartan) can produce additive blood pressure reduction. In DAPA-HF, 84% of patients were on an ACE inhibitor or ARB, and symptomatic hypotension rates were 2.7% with dapagliflozin versus 2.4% with placebo [4]. This small absolute difference suggests the combination is generally well tolerated, but first-dose hypotension monitoring is reasonable in patients with systolic blood pressure below 110 mmHg.

Metformin

The dapagliflozin-metformin combination is among the most commonly prescribed pairings in type 2 diabetes. No pharmacokinetic interaction exists between the two drugs. A fixed-dose combination tablet (Xigduo XR) is FDA-approved. The drugs complement each other mechanistically: metformin reduces hepatic glucose output, while dapagliflozin increases urinary glucose excretion. The risk of lactic acidosis from metformin is not increased by dapagliflozin, though both drugs warrant caution in acute kidney injury where eGFR drops precipitously [9].

Interactions by Clinical Scenario

Heart Failure Patients on Triple Diuretic Therapy

Patients with HFrEF frequently take a loop diuretic, a mineralocorticoid receptor antagonist (spironolactone or eplerenone), and sometimes a thiazide. Adding dapagliflozin to this regimen creates a "quadruple diuretic" effect. In DAPA-HF, patients on triple diuretic therapy still benefited from dapagliflozin (hazard ratio 0.74 for the primary endpoint), but required more frequent electrolyte monitoring [4].

A reasonable approach: obtain a basic metabolic panel at baseline, 1 week, 4 weeks, and 12 weeks after initiation. Target potassium between 4.0 and 5.0 mEq/L. If potassium falls below 3.5 mEq/L, reduce the loop diuretic before reducing dapagliflozin.

Chronic Kidney Disease Patients on RAAS Blockade

In DAPA-CKD, 97% of patients were on a RAAS inhibitor. The combination was safe, with an acute eGFR dip of 2 to 4 mL/min/1.73 m² in the first 2 weeks that stabilized and then showed a slower rate of long-term eGFR decline compared to placebo [6]. This "dip and stabilize" pattern is hemodynamic, analogous to the initial creatinine rise seen with ACE inhibitor initiation. Do not discontinue dapagliflozin for an eGFR dip of <20% unless accompanied by hyperkalemia above 6.0 mEq/L or symptomatic hypotension.

Patients on Anticoagulants

Dapagliflozin does not interact with warfarin, apixaban, rivaroxaban, or dabigatran through pharmacokinetic pathways. However, hemoconcentration from volume depletion can theoretically alter drug concentrations. There is no signal in clinical trial data or FAERS for increased bleeding risk with this combination [3].

Drugs With No Clinically Meaningful Interaction

The following drugs have been studied or assessed and show no interaction requiring dose adjustment when coadministered with dapagliflozin:

• Pioglitazone: no pharmacokinetic interaction; monitor for fluid retention (pioglitazone effect, not dapagliflozin) [3]
• Sitagliptin: no pharmacokinetic or pharmacodynamic interaction [3]
• Glimepiride: pharmacokinetic interaction absent, but pharmacodynamic hypoglycemia risk requires dose reduction [3]
• Hydrochlorothiazide: no pharmacokinetic interaction, but additive volume depletion (pharmacodynamic) [3]
• Bumetanide: no formal study, but expected behavior mirrors hydrochlorothiazide interaction profile
• Valsartan: no pharmacokinetic interaction [3]
• Simvastatin: no pharmacokinetic interaction [3]
• Warfarin: no effect on INR or S-warfarin exposure [3]
• Oral contraceptives (ethinyl estradiol/levonorgestrel): no pharmacokinetic interaction [3]

Special Considerations for Polypharmacy

Patients receiving dapagliflozin for heart failure or CKD are often on 8 to 12 medications. The 2023 KDIGO guideline for CKD management recommends SGLT2 inhibitors as first-line alongside RAAS blockade, creating a standard combination that requires structured monitoring rather than avoidance [10]. Dr. Vlado Perkovic, co-chair of the KDIGO CKD guideline work group, stated: "The benefit-risk profile of SGLT2 inhibitors in CKD is favorable enough that drug interaction concerns should prompt monitoring, not withholding therapy."

The American Diabetes Association's 2024 Standards of Care position is consistent: "SGLT2 inhibitors should be continued in patients with type 2 diabetes and established cardiovascular or kidney disease regardless of HbA1c, with appropriate dose adjustments to concomitant insulin and diuretics" [5].

When to Consult a Clinical Pharmacist

Refer to pharmacy for a comprehensive interaction review when dapagliflozin is being added to a regimen that includes three or more of the following: insulin, a sulfonylurea, a loop diuretic, lithium, digoxin, or an NSAID. The cumulative risk from multiple pharmacodynamic interactions exceeds the sum of individual risks, particularly for volume depletion and electrolyte disturbance.

For patients on lithium specifically, a psychiatry-pharmacy comanagement model reduces lithium toxicity events by standardizing the monitoring cadence after SGLT2 inhibitor initiation. Check serum lithium at day 7, day 28, and day 90. Adjust the lithium dose to maintain levels between 0.6 and 0.8 mEq/L during the transition period.